S3 guideline Atopic dermatitis: Part 2 ‐ Systemic treatment

Abstract

SummaryThe present S3 guideline was created based on the European English‐language S3 guideline, with special consideration given to the medical conditions in the German‐speaking region, and with additions from the previous German‐language version, in accordance with the criteria of the AWMF. This second part of the guideline addresses the systemic therapy of atopic dermatitis (AD). It covers topics such as the indication for systemic therapy in children, adolescents, and adult patients with AD. Furthermore, it addresses all medications approved for AD, such as the biologics dupilumab and tralokinumab, the Janus kinase inhibitors abrocitinib, baricitinib, and upadacitinib, as well as conventional immunosuppressive therapies with systemic glucocorticosteroids and ciclosporin. Additionally, it discusses systemic off‐label therapies. The first part of the guideline, published separately, includes the definition and diagnostic aspects of AD, describes topical therapy, non‐drug therapy approaches, and addresses aspects related to special patient groups.